# US 2019/0376965 A1 · Methods and materials for identifying and treating autoimmune gfap astrocytopathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376965 A1
- Document ID: US20190376965A1
- Status: Published application
- Kind: A1
- Application number: 16/331,853
- Filed: 2017-09-06
- Published: 2019-12-12
- Earliest claimed: 2016-09-09
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Vanda A. Lennon; Andrew McKeon; Boyan Fang; Shannon Hinson; Thomas J. Kryzer
- Web page: https://patentgrep.com/patent/US20190376965A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K 49/06: Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- G01N 2800/24: Immunology or allergic disorders
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This document provides methods and materials involved in identifying and treating autoimmune GFAP (glial fibrillary acidic protein) astrocytopathy, a novel meningoencephalomyelitis, in humans as well as methods and materials for identifying and offering early treatment for patients having autoimmune GFAP astrocytopathy whose autoantibody profile predicts a high likelihood of having underlying cancer (e.g., adenocarcinoma or teratoma).

## Claims

### Claim at position 1

1-4. (canceled)

### Claim 5

A method for treating an autoimmune GFAP astrocytopathy in a human, wherein said method comprises:
(a) identifying said human as having GFAP-specific IgG, and
(b) administering a steroid compound to said human.

### Claim 6 (depends on 5)

The method of claim 5, wherein said method comprises detecting the presence of said GFAP-specific IgG within a biological sample obtained from said human.

### Claim 7 (depends on 5)

The method of claim 5, wherein said sample is a cerebrospinal fluid sample.

### Claim 8

A method for treating an autoimmune GFAP astrocytopathy, wherein said method comprises administering a steroid compound to a human identified as having GFAP-specific IgG.

### Claim 9 (depends on 8)

The method of claim 8, wherein said steroid is a corticosteroid.

### Claim at position 7

10-15. (canceled)

### Claim 16

A kit comprising:
(a) a first antigen source comprising a GFAP polypeptide and lacking NMDA-R and AQP4 polypeptides,
(b) a second antigen source comprising a NMDA-R or AQP4 polypeptide and lacking GFAP polypeptides, and
(c) an anti-human IgG antibody.

### Claim 17 (depends on 16)

The kit of claim 16, wherein said first antigen source is a cell transfected to express said GFAP polypeptide.

### Claim 18 (depends on 16)

The kit of claim 16, wherein said GFAP polypeptide is a human GFAP polypeptide.

### Claim 19 (depends on 16)

The kit of claim 16, wherein said second antigen source comprises said NMDA-R polypeptide.

### Claim 20 (depends on 16)

The kit of claim 16, wherein said second antigen source comprises said AQP4 polypeptide.

### Claim 21 (depends on 16)

The kit of claim 16, wherein said second antigen source is a cell transfected to express said NMDA-R or AQP4 polypeptide.

### Claim 22 (depends on 16)

The kit of claim 16, wherein said second antigen source is a cell transfected to express said NMDA-R polypeptide and said AQP4 polypeptide.

### Claim 23 (depends on 16)

The kit of claim 16, wherein said NMDA-R polypeptide is a human NMDA-R polypeptide.

### Claim 24 (depends on 16)

The kit of claim 16, wherein said AQP4 polypeptide is a human AQP4 polypeptide.

### Claim 25 (depends on 16)

The kit of claim 16, wherein said anti-human IgG antibody is covalently attached to a label moiety.

### Claim 26 (depends on 25)

The kit of claim 25, wherein said label moiety is a florescent moiety.

### Claim 27 (depends on 16)

The kit of claim 16, wherein said kit comprises GFAP-specific IgG, NMDA-R-specific IgG, or AQP4-specific IgG.
